Tobias Schmidt Slørdahl (Tobias S Slørdahl)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 12

Top Topics

Multiple Myeloma

Endoplasmic Reticulum Stress

Signaling Pathway

Top Venues

Blood cancer journal

British journal of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Thomas Lund, Michael Tveden Gundesen, Annette Juul Vangsted, Carsten Helleberg, Einar Haukås, Trine Silkjær, Jon Thor Asmussen, Elena Manuela Teodorescu, Bo Amdi Jensen, Tobias Schmidt Slørdahl, Hareth Nahi, Anders Waage, Niels Abildgaard, Schjesvold Fredrik, null null
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease. Blood cancer journal 14 (1) (2024)
Nordberg Nørgaard Jakob, Kari Lenita Falck Moore, Tobias Schmidt Slørdahl, Anders Vik, Tor Henrik Anderson Tvedt, Schjesvold Fredrik
VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide population-based study. Blood cancer journal 14 (1) (2024)
Thomas Lund, Michael Tveden Gundesen, Annette Juul Vangsted, Carsten Helleberg, Einar Haukås, Trine Silkjær, Jon Thor Asmussen, Elena Manuela Teodorescu, Bo Amdi Jensen, Tobias Schmidt Slørdahl, Hareth Nahi, Anders Waage, Niels Abildgaard, Schjesvold Fredrik, null null
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease. Blood cancer journal 14 (1) (2024)
Thomas Lund, Michael Tveden Gundesen, Annette Juul Vangsted, Carsten Helleberg, Einar Haukås, Trine Silkjær, Jon Thor Asmussen, Elena Manuela Teodorescu, Bo Amdi Jensen, Tobias Schmidt Slørdahl, Hareth Nahi, Anders Waage, Niels Abildgaard, Schjesvold Fredrik, null null
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease. Blood cancer journal 14 (1) (2024)
Marie Røra, Margrete Skretting Solberg, Kari Lenita Falck Moore, Tobias Schmidt Slørdahl
Incidence and prevention of skeletal-related events in multiple myeloma patients: A population-based real-world experience. EJHaem 5 (4) (2024)
Nordberg Nørgaard Jakob, Kari Lenita Falck Moore, Tobias Schmidt Slørdahl, Anders Vik, Tor Henrik Anderson Tvedt, Schjesvold Fredrik
VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide population-based study. Blood cancer journal 14 (1) (2024)
Thomas Lund, Michael Tveden Gundesen, Annette Juul Vangsted, Carsten Helleberg, Einar Haukås, Trine Silkjær, Jon Thor Asmussen, Elena Manuela Teodorescu, Bo Amdi Jensen, Tobias Schmidt Slørdahl, Hareth Nahi, Anders Waage, Niels Abildgaard, Schjesvold Fredrik, null null
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease. Blood cancer journal 14 (1) (2024)
Nordberg Nørgaard Jakob, Kari Lenita Falck Moore, Tobias Schmidt Slørdahl, Anders Vik, Tor Henrik Anderson Tvedt, Schjesvold Fredrik
VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide population-based study. Blood cancer journal 14 (1) (2024)
Marie Røra, Margrete Skretting Solberg, Kari Lenita Falck Moore, Tobias Schmidt Slørdahl
Incidence and prevention of skeletal-related events in multiple myeloma patients: A population-based real-world experience. EJHaem 5 (4) (2024)
Nordberg Nørgaard Jakob, Kari Lenita Falck Moore, Tobias Schmidt Slørdahl, Anders Vik, Tor Henrik Anderson Tvedt, Schjesvold Fredrik
VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide population-based study. Blood cancer journal 14 (1) (2024)
Michael T Gundesen, Jon Thor Asmussen, Schjesvold Fredrik, Annette Juul Vangsted, Carsten Helleberg, Einar Haukås, Trine Silkjær, Elena Manuela Teodorescu, Bo Amdi Jensen, Tobias Schmidt Slørdahl, Hareth Nahi, Anders Waage, Niels Abildgaard, Thomas Lund, null null
Potential value of pre-planned imaging of bone disease in multiple myeloma. Blood cancer journal 13 (1) (2023)
Kristin Roseth Aass, Tonje Marie Vikene Nedal, Siri Anshushaug Bouma, Synne Stokke Tryggestad, Einar Haukås, Tobias Schmidt Slørdahl, Anders Waage, Therese Standal, Robin Mjelle
Comprehensive small RNA-sequencing of primary myeloma cells identifies miR-105-5p as a predictor of patient survival. British journal of cancer (2022)